ReviewInternational journal of molecular sciences2024
The Role of Fenugreek in the Management of Type 2 Diabetes.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Diabetes: A comprehensive review of the Indian landscape in contrast with global trends.World journal of diabetes · 2026Review
- Phytochemical evaluation, nutritional and pharmacological values ofFrontiers in chemistry · 2026Review
- Integrative Approach to Elucidate the Antidiabetic Efficacy of Cipadessa baccifera (Roth) Miq.: A Study Based on Metabolomics, Network Pharmacology, and Animal Models.Chemistry & biodiversity · 2026Article
- Transcriptome analysis of fenugreek under mixed saline-alkali stress.Frontiers in plant science · 2026Article
- Herbal Medicines in the Management of Diabetes Mellitus: Plants, Bioactive Compounds, and Mechanisms of Action.Biomolecules · 2025Review
- Optical and green catalytic properties of fenugreek water for diabetes and skincare treatments.Scientific reports · 2025Article
- Fenugreek seeds as a natural source of L-arginine-encapsulated lipid nanoparticles against diabetes.Scientific reports · 2025Article
- Exploring the relationship of complementary therapy use and medication adherence among patients with epilepsy.Journal of pharmaceutical policy and practice · 2025Article
- Characterization of bioactive compounds in fenugreek genotypes in varying environments: diosgenin, trigonelline, and 4-hydroxyisoleucine.Frontiers in plant science · 2025Article
- Mass Spectrometric Based Metabolomics of the Saudi Cultivar of Fenugreek (Pharmaceuticals (Basel, Switzerland) · 2024Article
- Reverse Gradient Distributions of Drug and Polymer Molecules within Electrospun Core-Shell Nanofibers for Sustained Release.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of people diagnosed with type 2 diabetes is on the increase worldwide. Of growing concern, the prevalence of type 2 diabetes in children and youths is increasing rapidly and mirrors the increasing burden of childhood obesity. There are many risk factors associated with the condition; some are due to lifestyle, but many are beyond our control, such as genetics. There is an urgent need to develop better therapeutics for the prevention and management of this complex condition since current medications often cause unwanted side effects, and poorly managed diabetes can result in the onset of related comorbidities. Naturally derived compounds have gained momentum for preventing and managing several complex conditions, including type 2 diabetes. Here, we provide an update on the benefits and limitations of fenugreek and its components as a therapeutic for type 2 diabetes, including its bioavailability and interaction with the microbiome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.